Management of RAASi-associated hyperkalemia in patients with cardiovascular disease

Renin–angiotensin–aldosterone system inhibitors (RAASi) reduce morbidity and mortality in heart failure (HF) with reduced ejection fraction in a dose-dependent manner. They also have a positive impact in other cardiovascular diseases (CVDs). However, RAASi may induce hyperkalemia, a potentially life...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva-Cardoso, José, Brito, Dulce, Frazão, João Miguel, Ferreira, Aníbal, Bettencourt, Paulo, Branco, Patrícia, Fonseca, Cândida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149346/
https://www.ncbi.nlm.nih.gov/pubmed/33599908
http://dx.doi.org/10.1007/s10741-020-10069-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149346/
https://www.ncbi.nlm.nih.gov/pubmed/33599908
http://dx.doi.org/10.1007/s10741-020-10069-3

Ejemplares similares